Beyond hormone replacement: Quality of life in women with congenital hypogonadotropic hypogonadism by Dzemaili S et al.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This work is licensed under a  
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence 
 
 
Newcastle University ePrints - eprint.ncl.ac.uk 
 
Dzemaili S, Tiemensma J, Quinton R, Pitteloud N, Morin D, Dwyer AA.  
Beyond hormone replacement: Quality of life in women with congenital 
hypogonadotropic hypogonadism.  
Endocrine Connections 2017, 6(6), 404-412. 
 
 
Copyright: 
© 2017 The authors. This work is licensed under a Creative Commons Attribution-NonCommercial-
NoDerivatives 4.0 International License. 
DOI link to article: 
https://doi.org/10.1530/EC-17-0095  
Date deposited:   
20/10/2017 
This work is licensed under a Creative Commons 
Attribution-NonCommercial-NoDerivatives 4.0 
International License.
DOI: 10.1530/EC-17-0095
http://www.endocrineconnections.org © 2017 The authors
Published by Bioscientifica Ltd
6
6
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
6:6 404–412S Dzemaili et al. Beyond hormone replacement: women with CHH
En
d
o
cr
in
e 
C
o
n
n
ec
ti
o
n
s
Open Access
Beyond hormone replacement: 
quality of life in women with 
congenital hypogonadotropic 
hypogonadism
Shota Dzemaili1, Jitske Tiemensma2, Richard Quinton3, Nelly Pitteloud4, 
Diane Morin1,5 and Andrew A Dwyer1,4
1University of Lausanne, Institute of Higher Education and Research in Healthcare, Lausanne, Switzerland
2University of California Merced, Psychological Science, Merced, CA, USA
3Department of Endocrinology, Institute for Human Genetics, University of Newcastle-upon-Tyne, 
Newcastle-upon-Tyne, United Kingdom
4Endocrinology, Diabetes & Metabolism Service of the Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
5Faculty of Nursing Science, Laval University, Québec City, Canada
Abstract
Objective: Little is known about how women with isolated GnRH deficiency cope with 
their condition. This study aimed to examine the health and informational needs of 
women with congenital hypogonadotropic hypogonadism (CHH) and evaluate if their 
experiences differ from women with more common forms of infertility.
Design: Cross-sectional, multiple methods study using web-based data collection to 
reach dispersed rare disease patients.
Methods: A community-based participatory research framework was employed to 
develop an online survey and collect quantitative and qualitative data. Adult women 
diagnosed with CHH who had received at least one year of hormonal treatment 
completed the Morisky Medication Adherence Scale, Revised Illness Perception 
Questionnaire and Zung Self-Rating Depression Scale. Information on health care 
experiences, treatment outcomes and patient-reported challenges were also collected.
Results: Women (n = 55) were often diagnosed late (20.7 ± 7.4, range: 10–48 years) and 
16/20 patients receiving fertility treatment conceived. Poor adherence was frequently 
observed (34/55) while more than half (27/49) reported a gap in treatment exceeding 
a year. Low adherence correlated with depressive symptoms (r = 0.3, P > 0.05). Negative 
illness perceptions were pervasive and 30/55 exhibited some depressive symptoms – 
significantly greater than women with common female factor infertility (P < 0.01). 
Symptoms were underappreciated by providers as only 15 of 55 patients had discussions 
about psychological services. Women identified isolation, need for information and 
finding expert care as challenges to living with CHH.
Conclusions: Despite being a treatable form of female infertility, the presumable 
availability of treatment does not necessarily ensure adequate quality of life for women 
with isolated GnRH deficiency.
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Introduction
Infertility affects ~10–15% of women globally and is a 
significant health concern (1). Sometimes referred to as 
the pilot light of reproduction, gonadotropin-releasing 
hormone (GnRH) secretion is essential for developing 
and maintaining the reproductive capacity (2). Acquired 
GnRH deficiency (i.e. hypothalamic amenorrhea) is a 
common cause of secondary amenorrhea that is reversible 
(3). More severe forms of GnRH deficiency, such as 
congenital hypogonadotropic hypogonadism (CHH), 
are much less common. However, CHH is responsive to 
hormonal therapy and is a treatable form of infertility that 
does not necessarily require invasive assisted reproduction 
techniques (4).
In its most severe form, CHH presents as a complete 
absence of puberty with undetectable serum gonadotropins 
and hypogonadal sex steroid levels. Clinical presentation 
is variable: some patients display partial puberty (5), there 
is a wide range of associated phenotypes (e.g. absent 
sense of smell, skeletal anomalies, mirror movements, 
renal agenesis) and cases of reversal have been reported 
(6). Similarly, genetic etiology is heterogeneous with 
more than 25 genes having been identified in relation 
to CHH and the genetic architecture can sometimes be 
complex as evidenced by oligogenicity (4). CHH is rare 
(1:4000–10,000) and there is a striking sexual discordance. 
Combining three large patient cohorts from the United 
States (n = 250) (7), United Kingdom (n = 215) (8) and 
France (n = 334) (9) reveals the male to female ratio to 
be 3.6–1. Yet, unlike many other rare disorders, effective 
treatments are available. Hormone replacement in the 
form of low-dose estradiol (titrated over time) is the 
standard treatment for younger hypogonadal women 
to induce secondary sexual characteristics and menses 
(4). Combined gonadotropin therapy or physiologic 
treatment with pulsatile GnRH are equally effective for 
inducing fertility in the vast majority of cases (10).
Compared to fertile counterparts, women with 
infertility have higher levels of stress, anxiety and 
depression, and all of which can erode the quality of life 
(11). However, little is known about the experiences of 
women with CHH and how they cope with their condition. 
There is a body of literature on quality of life issues in 
women with primary infertility (i.e. Turner syndrome, TS) 
(12). However, differences in terms of timing of diagnosis, 
phenotype and fertility potential preclude extending 
findings from women with a hypogonadotropic cause of 
infertility (TS) to those with a hypogonadotropic etiology 
(CHH). Notably, conducting research in rare disease 
patients is challenged by the fact that these patients are 
dispersed and difficult to reach. Therefore, the purpose of 
this study was to partner with patients and use web-based 
data collection to reach women with CHH to conduct a 
needs assessment to identify targets for developing more 
patient-centered approaches to care for these endocrine 
patients.
Subjects and methods
Design and subjects
This cross-sectional needs assessment employed multiple 
methods within a community-based participatory research 
framework (13). We engaged patient community leaders 
in developing content and validating the online survey as 
well as for recruitment. Patients were identified via patient-
oriented social media sites (i.e. Facebook, Rareconnect.
org) and the international network studying GnRH 
deficiency (COST Action BM1105, www.gnrhdeficiency.
eu) over a 14-month period (October 2014–December 
2015). CHH was defined as previously reported (5) and 
diagnosis was confirmed in a 40% random sample of 
respondents as described (14). Adult women (18+ years) 
with CHH who had been on hormonal treatment for at 
least one year were included in the analysis. The project 
was reviewed and approved by the local ethics committee, 
and all participants provided opt-in electronic consent.
Needs assessment survey
We co-constructed an online survey with patients 
including items on patient demographics, health literacy 
(15), medical history, health care interactions, sexuality 
as well as several validated questionnaires. The selection 
of questionnaires was based on their relevance, validity 
and widespread use that facilitate comparison with 
particular patient populations of interest (i.e. women 
with infertility and men with CHH and patients with 
rare endocrine disorders and chronic conditions). The 
Morisky Medication Adherence Scale (MMAS) is an 8-item 
instrument that assesses medication taking behavior to 
determine low, medium or high adherence (16, 17, 18). The 
Zung Self-Rating Depression Scale (SDS) is a widely used, 
validated 20-item instrument quantifying the severity 
of affective, somatic, psychomotor and psychological 
depressive symptoms (19, 20). The Illness Perception 
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Questionnaire – Revised (IPQ-R) includes 38 statements to 
assess emotional and cognitive representations of illness 
spanning 7 dimensions: timeline acute/chronic (beliefs 
about the chronic nature of the condition), timeline cyclical 
(beliefs regarding the cyclical nature of the condition), 
consequences (negative consequences of the disease), 
personal control (perceived personal controllability of 
the disease), treatment control (perceived treatment 
controllability of the disease), emotional representations (the 
emotional responses generated by the illness) and illness 
coherence (personal understanding of the disease) (21). 
Additionally, patients had the opportunity to provide a 
free text response identifying what they perceive to be the 
most challenging aspects of living with CHH.
Reference populations
To provide context for the depressive symptoms in 
women with CHH, SDS scores were compared to: (a) men 
with CHH (n = 101) (22), (b) women seeking assisted 
fertility treatment (n = 872) (11) and (c) community-based 
rates in a healthy, non-psychiatric population (n = 292) 
who completed the SDS monthly over the course of one 
full year (23). Because there are no normative scores 
for the IPQ-R for the general population (i.e. healthy 
adults), comparisons were made to patients with acute or 
chronic pain (24), men with CHH (22) and patients with 
acromegaly (24) to provide a clinical context for these 
data. Age at CHH diagnosis was compared to a population-
based sample for age of menarche (25).
Analysis
Descriptive statistics were used to present survey data. 
Comparisons between groups were performed using 
Student’s t-test or Mann–Whitney rank-sum test as 
appropriate. Categorical values were compared using chi-
square test while Pearson product–moment correlations 
were performed to assess the associations between survey 
data. IPQ-R subscales were compared across the CHH 
and reference groups using ANOVA with Bonferroni 
post hoc correction for multiple comparisons. Z-scores 
were used to assess the differences in the proportion of 
patients exhibiting depressive symptoms compared to 
community base rates. Survey data were analyzed using 
PASW Statistics, version 17.0.2 (SPSS Inc., Chicago, IL). All 
data are presented as mean ± s.d. unless otherwise noted 
and a P ≤ 0.05 was considered statistically significant. 
Open-ended responses were analyzed using NVivo11 
(QSR International PSY Ltd., Melbourne Australia). 
Deductive thematic analysis (deductive coding) was 
conducted by two independent investigators (SD and AD). 
Meaningful units were coded. These codes were sorted 
into categories and themes in an iterative process and 
consensus was achieved by discussion. The most frequent 
themes were given particular emphasis (26).
Results
The web-based survey was online for 14 months during 
which time 68 women responded. After removing 
incomplete survey responses and those not meeting 
inclusion criteria, 55 surveys were included for analysis. 
Given the rarity of women with CHH (7, 8, 9), it appears 
that the combination of community partnerships and 
social media recruitment were effective for reaching 
these dispersed patients (14). Patient sociodemographic 
characteristics are depicted in Table 1. The women ranged 
in age from 18 to 68  years (mean 35 ± 10, median 34), 
were well-educated (44/55, university or higher) with 
adequate health literacy and the majority of women were 
employed (41/55).
Table 1 Sociodemographic information of women with 
CHH (n = 55).
 n (%)
Age (years)
18–29 16 (29%)
30–39 25 (46%)
40–49 9 (16%)
50–59 4 (7%)
60+ 1 (2%)
Education  
High school/vocational 10 (18%)
University 28 (51%)
Post-graduate 16 (29%)
No response 1 (2%)
Health literacy (25)  
Adequate literacy 45/55 (82%)
Inadequate literacy 10/55 (18%)
Employment  
Working full-time 32 (58%)
Working part-time 9 (16%)
Not working/unemployed 8 (15%)
Retired 1 (2%)
Student 5 (9%)
Relationship status  
Married 21 (38%)
In a relationship 14 (25%)
Single 9 (16%)
Never been in a relationship 4 (7%)
Divorced 7 (13%)
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Given that menarche is an important single-event 
signpost of puberty and that 90% of CHH women 
present with primary amenorrhea (5), earlier diagnosis 
and treatment would be expected compared to male 
counterparts who lack such a hallmark. However, we 
found no such pattern (females: n = 55; 95% CI: 18.7–22.7, 
males: n = 101; 17.6–20.2 years; P = 0.16) (22). The women 
were diagnosed between 10 and 48 years of age (Fig. 1A), 
and more than half (n = 32) had received any meaningful 
treatment prior to age 18 years (95% CI: 17.2–20.6 years). 
Nearly two-thirds (34/55) of survey respondents had been 
seen at a specialized academic medical center (Table  2). 
Twenty women underwent fertility-inducing treatment, 
two-thirds (13/20) of whom at an academic medical center 
and the vast majority (16/20) successfully conceived, 
consistent with rates previously reported (27, 28), and in 
line with male CHH counterparts (95% CI: 60–85%) (29). 
In total, nearly half (25/55) the women had undergone 
genetic testing yet significantly fewer (11/55, P < 0.005) 
received genetic counseling. Among surveyed patients, 
women receiving fertility-inducing treatment were not 
more likely to have genetic testing (12/20, P = 0.10) or 
counseling (5/20, P = 0.48) compared to the larger group.
All respondents included in the analysis had been 
on treatment for at least one year. Women completed 
the MMAS to assess adherence behavior (Table  2) and 
provided self-reported longest duration off treatment 
(Fig. 1B). Notably, MMAS scores indicated low adherence 
in nearly two-thirds (34/55) of women. Lifetime duration 
of treatment was weakly correlated with MMAS (r = 0.29, 
P < 0.05). Only 11/49 reported never having a lapse in 
treatment – a proportion similar to those exhibiting 
the highest level of adherence on the MMAS (Table  1). 
However, more than half (27/49) reported long gaps in 
treatment (i.e. 12  months or longer). Similarly, 18/43 
claimed to have gone 2 years or longer without seeing a 
health care provider (data not shown).
Across IPQ-R dimensions, women and men had 
comparable perceptions of their CHH with scores indicating 
significant emotional impact and negative consequences 
(22) (Table 3). These findings extend the findings of a small 
qualitative study including interviews with 5 women with 
Table 2 Health care experiences of women with CHH (n = 55).
 n (%)
Medical history
Seen at a specialized academic 
medical center
34 (62%)
Genetic testing performed 25 (45%)
Genetic counseling received 11 (20%)
Sought psychological counseling 16 (29%)
Health care interactions  
Provider understands medical 
aspects of CHH
28 (51%)
Provider understands patient’s 
feelings of living with CHH
14 (25%)
Provider discussed or gave referral 
for counseling
15 (27%)
Experienced discrimination in the 
health care system
15 (27%)
Treatment and adherence  
Duration of treatment: mean ± s.d. 
(range, median)
16 ± 10 years (1–42, 17)
MMAS low adherence 34 (62%)
Medium adherence 12 (22%)
High adherence 9 (16%)
Fertility outcomes  
Received fertility-inducing 
treatment
20/55 (36%)
Biologic children 16/20 (80%)
MMAS is protected by US copyright laws. Permission for use is required. A 
license agreement is available from: Donald E. Morisky, ScD, ScM, MSPH, 
Professor, 294 Lindura Ct., Las Vegas, NV 89138-4632.
Figure 1
Age at CHH diagnosis and self-reported 
adherence to treatment. (A) Age at CHH 
diagnosis for 55 women ranged from 10 to 
48 years. The mean age at menarche for 
Caucasian females is shown as a horizontal line, 
and the shaded region depicts ± two s.d. (36). 
Only 11/55 women were diagnosed by age 15 
years. (B) Self-reported adherence to treatment 
(n = 49). Approximately one-quarter of 
respondents reported never having a gap in 
treatment. In total, more than half (27/49) 
reported a gap in treatment of a year or longer. 
Similarly 20/46 women reported having a lapse in 
health care exceeding one year (data not shown). 
Age at diagnosis was moderately correlated with 
duration of gap in health care (r = 0.56, P < 0.001).
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CHH (30). Women with CHH perceived more negative 
consequences of their illness compared to both patients 
with acute pain and patients with acromegaly (both 
P < 0.01) yet less than patients with chronic pain. The 
negative emotional impact of CHH was larger than that 
in patients with acromegaly (P < 0.01) but not different 
from patients with acute or chronic pain. Both negative 
consequences and emotional impact were modestly 
correlated with poorer medication adherence (r = 0.298 and 
r = 0.33 respectively, both P < 0.05). Furthermore, females 
with CHH perceived less personal control over their 
illness than patients with acute pain (P < 0.01), but did not 
differ from patients with chronic pain or acromegaly. In 
terms of treatment control, females with CHH perceived 
less treatment control than patients with acute pain or 
acromegaly (both P < 0.01), but more treatment control 
than patients with chronic pain (P = 0.01). Lastly, women 
with CHH exhibited the highest score on illness coherence 
compared to patients with acute or chronic pain (both 
P < 0.01). This better understanding of their illness could 
be related to the congenital nature of CHH.
More than half the women (30/55) exhibited some 
depressive symptoms. This is significantly increased 
compared to the 9% observed in a community dwelling 
non-psychiatric population (P < 0.001) (23) yet similar 
to their male CHH counterparts (64/100, P = N.S.) (22). 
Compared to those presenting with more common female 
infertility (14.7% of 872 women) (11), women with CHH 
were more likely to exhibit depressive symptoms (P < 0.01), 
and this relationship persisted when we limited the 
analysis to only those patients (25.6% of 193 women) with 
female factor infertility (P < 0.01). In total, 14/55 women 
with CHH exhibited mild depressive symptoms, 9/55 had 
moderated symptoms similar to the type of depression 
treated in an ambulatory setting while 7/55 had severe 
depressive symptoms akin to major depressive disorder. We 
found depressive symptoms were moderately correlated 
with poorer medication adherence (r = 0.3, P < 0.05) 
consistent with prior studies in patients with chronic 
diseases (31). Depressive symptoms were also correlated 
with illness perception dimensions. We observed a strong 
correlation between depressive symptoms and negative 
emotional impact of CHH (r = 0.6, P < 0.0001), a moderate 
relationship with consequences (r = 0.42, P < 0.01) and a 
weak association with illness coherence – how one makes 
sense of their condition (r = 0.35, P < 0.01).
Importantly, the increased depressive symptoms 
appear to be underappreciated as only 15 women stated 
that their provider had discussed or provided a referral 
for psychological counseling. Half the patients (28/55) 
perceived that their health care provider well understood 
the medical aspects of their GnRH deficiency yet 
significantly fewer felt that their provider understood 
how patients feel about living with CHH (14/55, P < 0.01). 
Women with CHH were more likely than their male 
counterparts to have been in a relationship and sexually 
active (both, P < 0.05) (32). Despite this, nearly all women 
(51/55) cited issues of body image concerns, with 44/55 
reporting feelings of shame or embarrassment about their 
body and over half (32/55) found intimate relationships 
difficult and had experienced teasing or ridicule about 
their lack of development (31/55).
Qualitative data were also collected as part of 
the survey. Patients were asked to describe the most 
challenging aspect of living with CHH and approximately 
two-thirds (36/55) responded. Responses were coded and 
the 61 topics thematically clustered in three categories: (i) 
isolation and insecurity (n = 24), (ii) need for information 
and support (n = 24) and (iii) delayed diagnosis and finding 
expert care (n = 13). A table with representative quotes is 
provided in the online supplemental file (see section on 
supplementary data given at the end of this article). We 
also asked patients where they sought information about 
their condition. Nearly all women (52/55) reported that 
they found information about their condition on the 
internet, 46/55 via online community and social media 
(i.e. Facebook, Rareconnect.org) and 44/55 were informed 
by health care professionals. Despite high education and 
Table 3 Comparison of IPQ-R scores between female CHH patients and other patient groups.
IPQ-R CHH (women) (n = 55) CHH (men) (n = 101) acute pain (n = 35) chronic pain (n = 63) Acromegaly (n = 81)
Timeline (acute/chronic) 27.2 (3.6) 26.7 (3) 13.4 (5)** 23.1 (4)** 22.9 (6)**
Timeline (cyclical) 9.2 (3.9) 9.7 (4) 9.4 (3) 12.9 (4)** 10.1 (4)
Consequences 20.0 (5.1) 21.3 (4) 14.2 (4)** 23.5 (4)** 16.9 (5)**
Emotional representations 17.8 (6.2) 19.2 (6) 16.1 (4) 19.8 (4) 12.6 (4)**
Personal control 19.6 (4.9) 19.9 (5) 22.9 (4)** 18.4 (4) 17.5 (5)
Treatment control 16.1 (3.3) 15.5 (4) 19.4 (3)** 14.2 (3)* 18.1 (3)**
Illness coherence 16.5 (4.7) 18.1 (4) 9.3 (3)** 13.4 (5)** 17.5 (3)
Data are mean (s.d.), *P < 0.05 compared with CHH (women), **P < 0.01 compared with CHH (women).
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health literacy levels, approximately half (27/55) sought 
information from the medical literature. Patients rated 
health care professionals as the most important source 
of information followed by online community and the 
Internet. Ratings of importance were not statistically 
significant between these sources (P = 0.13).
Discussion
We found that women with CHH are often diagnosed 
late and experience significant physical, social and 
psychological consequences in relation to their condition. 
These findings have implications for developing more 
patient-centered approaches to care for these women. 
This cross-sectional study of 55 women is perhaps the 
most robust portrayal of this patient population to date. 
Data on women with CHH are scant with only a handful 
of single-center studies reporting on very small samples 
(i.e. n < 15). Additionally, patients were involved in 
developing the study – this strengthens our confidence 
that the identified targets for improving care are aspects 
that matter to patients.
Some aspects of this study may limit the ultimate 
transferability of the findings to all women with CHH. 
First, these patients were well educated with high levels 
of health literacy. Second, the inherent Anglophone 
bias should engender caution in considering cultural 
equivalence. Third, given the sample size, we may be 
underpowered in some of our analyses. Indeed, difficulty 
in recruiting adequate numbers of patients with rare 
diseases is widely acknowledged. This challenge informed 
our strategy of using the Internet and patient-oriented 
social media to reach these dispersed patients, which 
we acknowledge as a potential source of sampling bias. 
Finally, self-report nature of the instruments employed 
has its own limitations, albeit our goal was to better 
understand patient perspectives to identify the unmet 
needs as an initial step in developing more patient-
centered approaches to care.
Data on the age of diagnosis in CHH women comprise 
a single article (n = 5; mean: 23 ± 9, range: 12–35, median 
21 years) (30) along with some unpublished historic data 
(females: n = 38; mean: 18.2 ± 5, range: 10–53 years) (33). 
We found women with CHH are often diagnosed quite 
late and only 58% had received treatment prior to age 18 
years. It is well established that later induction of puberty 
for adolescent girls with TS is associated with poor self-
esteem, difficult social adjustment and diminished sex 
life (34, 35). Further, late diagnosis (and initiation of 
treatment) negatively impacts psychosexual development 
in men with CHH (32). Thus, greater attention to earlier 
detection and timely initiation of sex steroid therapy 
seems warranted.
The vast majority (16 of 20) of women who 
underwent fertility treatment were able to conceive, in 
line with published literature (27, 28). Notably, relatively 
few (11/55) women had received genetic counseling. This 
is surprising given that the American College of Medical 
Genetics considers abnormal pubertal timing a clinical 
presentation requiring referral to a medical genetics 
professional (i.e. genetic counselor) (36). Further, both the 
European Society of Human Genetics and the European 
Society of Human Reproduction and Embryology consider 
genetic counseling necessary when genetic factors are 
related to the cause of infertility (37). However, in our 
cohort, women receiving fertility-inducing treatment 
were no more likely to have genetic testing or counseling. 
These data suggest either lack of awareness of the 
importance of genetic counseling for these patients or 
may reflect inadequate access to specialists with sufficient 
understanding of the sometimes complex genetics of 
CHH (38). Improved access to genetic counseling appears 
to be a relevant target for enhancing patient care.
Long-term adherence to treatment was problematic as 
more than half of women had a gap in care of a year or 
longer. Without treatment, these women rapidly become 
hypogonadal, with deleterious impact on mood, well-
being, sex life and bone health. A Finnish cohort of 24 
men and 9 women found patients with the longest gaps 
in treatment exhibited the most impaired bone density 
(39). Additionally, risk for osteopenia/osteoporosis may 
be further compounded by late diagnosis, as up to 90% 
of adult bone mass is accumulated during adolescence 
(40). Delays in diagnosis (and treatment initiation) 
could prolong estrogen deficiency thus impairing bone 
mineralization. These data highlight the importance of 
adequate hormone replacement and ongoing follow-up 
to monitor bone density and adherence as well as the role 
for a coordinated transition to adult services to facilitate 
continuity of care (4, 39, 41).
Women had negative illness perceptions yet 
exhibited relatively high scores on illness coherence. 
Interestingly, CHH women who had received fertility 
treatment (and were able to conceive) had significantly 
lower ratings of negative consequences (P < 0.05) and 
emotional impact (P < 0.05) compared to those without 
children. While the sample is small, this may represent 
a psychological buffering effect of successful fertility 
treatment. We did not employ a formal health-related 
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quality of life (HR-QoL) instrument in this study; yet, 
the negative illness perceptions and increased depressive 
symptoms observed in women with CHH are consistent 
with impaired HR-QoL. A recent study of women with 
TS showed impaired HR-QoL compared to controls (35). 
Interestingly, the study included 21 women with other 
types of congenital hypogonadism (14 with CHH, 7 with 
46XX gonadal dysgenesis) whose SF-36 scores were quite 
similar. A subset of these patients completed the Female 
Sexual Function Index revealing impaired sexual desire, 
arousal, lubrication, orgasm and global satisfaction 
compared to controls (35). Similarly in our cohort, body 
image concerns were pervasive and the majority of women 
stated that intimate relationships were difficult. A recent 
study of young adults with CHH during transition found 
that few young women felt adequately informed about 
sexuality (2/7), intimate relationships (1/7), potential 
future fertility (1/7) or intercourse/potential discomfort 
with sex (0/7) (42). These current data underscore the 
need for appropriate anticipatory guidance on the topics 
of sexuality and intimate relationships.
The qualitative data analysis suggests that women 
struggle with feelings of isolation and finding expert care. 
They frequently reported having used the Internet and 
social media to learn about their condition and to find 
support from other patients (14). The Pew Foundation 
identified patients with a rare disease as ‘Internet power-
users’ (43), which aligns with our findings. We have 
previously shown that Web-based modalities are used 
by and acceptable to patients with CHH (14). This may 
present a novel avenue for reaching these dispersed 
patients, engaging them and promoting health and 
self-management. The Institute of Medicine defines 
patient-centered care as being guided by patient values 
and is both respectful of, and responsive to individual 
preferences, needs and values (44). The Picker Principles 
of patient-centered care (45) provide a useful framework 
for developing more patient-centered approaches to care. 
Accordingly, we have charted the findings from the present 
study onto this framework along with suggested avenues 
for translating the results of this study into improved care 
for women with CHH (see supplemental file).
In summary, this participatory, multiple methods 
needs assessment identifies that women with CHH 
frequently have lengthy gaps in treatment/care, perceive 
their condition to have a significant psychosocial impact 
on their life and exhibit increased depressive symptoms. 
Care for these women could be improved by earlier 
diagnosis and timely initiation of treatment, greater access 
to genetic counseling and providing accurate information 
about CHH (and fertility treatment) as well as offering 
professional and peer-to-peer psychological support. The 
Internet is effective for reaching and connecting dispersed 
patients, and Web-based platforms may hold promise for 
delivering patient-centered interventions to empower 
patients for improved self-management and adherence.
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